Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Vermont
About this trial
Among individuals with opioid use disorder (OUD), posttraumatic stress disorder (PTSD) presents a significant clinical challenge. The prevalence of PTSD is substantially higher in individuals with OUD than in the general population, with nearly 90% reporting lifetime trauma exposure and 33% meeting diagnostic criteria for PTSD. The primary objective of this study is to evaluate the efficacy of a novel telemedicine-delivered prolonged exposure therapy protocol for improving PE attendance and reducing PTSD symptom severity in individuals with concurrent PTSD and OUD.
Eligibility criteria
Qualifiers
>18 years old
Maintained on a stable methadone or buprenorphine dose for >1 month prior to the study
Meet current DSM-5 posttraumatic stress disorder criteria based on the Clinician Administered PTSD Scale for DSM-5
Participants receiving psychotropic medications must be maintained on a stable dose for >1 month prior to enrollment.
Disqualifiers
Current delusions or hallucinations, unstable bipolar disorder, imminent risk for suicide as assessed by the Mini International Neuropsychiatric Interview
Cognitive impairment as evidenced by scores <22 on the Videoconference-based Mini Mental Status Examination (MMSE; Folstein, et al., 1975)
Enrolled in another ongoing evidence-based treatment for PTSD.
Pregnancy as verified by pregnancy test
Trial design
Treatments tested in this trial
- Prolonged exposure therapy
- Financial incentives
- Treatment as usual
Treatment groups
135 Participants
are divided into 3 treatment groupsSponsors and collaborators
University of Vermont
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov